Table B3.

Therapeutic Breakout 3 Dopamine agonists

Antiparkinsonian effects when used as monotherapy or as an adjunct to levodopa
Reduced risk for developing levodopa-related motor complications
Do not generate oxidative metabolites
Levodopa-sparing effect
Potential neuroprotective benefits
Neuropsychiatric side effects (especially hallucinations and psychosis)
Agonist-specific side effects (erythromelalgia, ankle edema)
Sedative side effects
Do not completely prevent development of levodopa-related motor complications
Do not treat all features of PD, such as freezing, postural instability, autonomic dysfunction, dementia
Do not stop disease progression